Connecting investors and companies

Projektet är en betydande drivkraft för företagets volymutveckling under de kommande två åren.

Bittium utvecklar taktisk kommunikation för att fungera utan störningar även under aktiv bekämpning av fientliga drönare.

I denna översikt går vi igenom Oriolas balansräkning.

Hafnia delivered its strongest quarter of 2025 in Q4, reporting net profit of USD 110m and bringing full-year earnings to USD 340m. Despite a softer first half as rates came off their 2024 cyclical peaks, the company generated USD 560m in adjusted EBITDA and returned 88% of net profit to shareholders through dividends and buybacks,  paying USD 0.55/share for the full year.

AbbVie today reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra's out-licensed long-acting amylin analog. The study demonstrated dose-dependent weight loss ranging from -7.75% to -9.79% at week 12 for weekly dosing cohorts, and -7.86% to -9.73% at week 13 for less frequent dosing regimens (every other week and monthly after week 5), compared to approximately -0.25% for placebo.

14:34

Scanfil's revenue decreased by 1% in Q4.

2025 was a pivotal year for Gubra, with revenue of DKK 2.6bn and operating profit of DKK 2.2bn, driven by the landmark out-licensing agreement with AbbVie for the long-acting amylin analogue ABBV-295, with USD 350m in upfront payment, and DKK 1.1bn well-positioned to drive further development   2025 also marked the beginning of a broader transformation evolving from an obesity-focused biotech into a broader, more diversified life science company, with the new Ventures unit set to incubate focused companies in therapeutic areas beyond the core pipeline, with the first venture planned for H2 2026. The company has announced ambitions to establish new flagship therapeutic areas beyond obesity by 2030, and the CRO platform is expanding into new service areas, including sarcopenia and women’s health.

Robit meddelade på fredagen att de har mottagit en stämningsansökan från Sandvik gällande ett påstått patentintrång i en borrkronelösning.

Förra veckan var en tydlig nedgångsvecka på både den amerikanska och europeiska aktiemarknaden. Geopolitiska risker uppenbarade sig för investerare, och oljepriset har stigit kraftigt. På måndagsmorgonen hade priset på Brent-råolja stigit med 25 % till 115,5 dollar/fat, efter att redan ha ökat med 35 % förra veckan.

Additional purchases by the main owner strengthen our view that the stock is currently clearly undervalued.

En rörig rapport sätter punkt för uppdelningen och inleder en ny era för Talenom.

Vi har sänkt våra tillväxtestimat för de närmaste åren något, drivet av ett svagt orderingång under Q4, även om vi ser att det nyligen höjda konsumentenergipriset kan vara en potentiell efterfrågedrivare för eldstäder.

Tokmanni's Q4 report was lackluster overall, even though the company managed to improve its result.

Aiforia’s H2 revenue surpassed our expectations, and the earnings were in line with our estimate.

Componenta's financial statement release published on Friday was better than we expected across the board, with all key figures exceeding our forecasts.

Today, we have updated our research on TORM, one of the world's largest product tanker companies with a fleet of 93 vessels transporting refined oil products such as gasoline, diesel, and jet fuel across global trade routes. The company operates primarily in the spot market through its integrated One TORM platform, which consistently delivers market-leading freight rates per vessel.

Higher-than-expected revenue also boosted EBITDA beyond our estimates.

Meddelandet medför tekniska ändringar i våra estimat.